OKYO Pharma Limited (OKYO) News
Follow OKYO Pharma Limited (OKYO) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 8 public stories across 7 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
L
OKYO Pharma Presents and Participates at Upcoming Ophthalmic Scientific Conferences
LONDON and NEW YORK, Sept. 29, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain (N
NEWS | Sep 29, 2026, 11:08 AM UTC
L
OKYO Pharma to present at ESCRS 2026 iNovation Day
OKYO Pharma said it will present at Ophthalmology Futures European Forum and iNovation Day at ESCRS 2026.
EQUITY | Sep 09, 2026, 11:02 AM UTC
L
OKYO - OKYO Pharma to Participate in a Fireside Chat at the Cantor Global Healthcare Conference
OKYO - OKYO Pharma to Participate in a Fireside Chat at the Cantor Global Healthcare Conference
EQUITY | Sep 08, 2026, 11:01 AM UTC
L
OKYO - Another insider buy: Okyo Pharma Limited, a clinical-stage biopharmaceutical company developing investigational Therapies for the tre
OKYO - Another insider buy: Okyo Pharma Limited, a clinical-stage biopharmaceutical company developing investigational Therapies for the treatment of neuropathic corneal pain (NCP) and anterior segment eye diseases, toda
EQUITY | Jul 23, 2026, 11:36 AM UTC
L
OKYO Pharma Limited today announced that Okyo Pharma's Chief Medical Officer, Flavio Mantelli, Md, PhD, has purchased 20,000 of the Company'
OKYO Pharma Limited today announced that Okyo Pharma's Chief Medical Officer, Flavio Mantelli, Md, PhD, has purchased 20,000 of the Company's ordinary shares on Nasdaq at $1.40 per share.
EQUITY | Jul 22, 2026, 11:28 AM UTC
L
OKYO - Okyo Pharma Chairman Gabriele Cerrone Purchases 25,000 Ordinary Shrs Okyo Pharma Cerrone Holds 20.51% of Issued Shr Cap
OKYO - Okyo Pharma Chairman Gabriele Cerrone Purchases 25,000 Ordinary Shrs Okyo Pharma Cerrone Holds 20.51% of Issued Shr Cap
EQUITY | Jul 21, 2026, 11:23 AM UTC
L
OKYO Pharma Receives 'Positive Feedback' From FDA Meeting About Phase 3 Trial of Urcosimod to Treat Neuropathic Corneal Pain
() -- OKYO Pharma (OKYO) said Wednesday it has received "positive feedback" from its US Food and Drug Administration Type D meeting concerning its lead drug candidate urcosimod to treat neuropathic corneal pain. The biop
REGULATION | Jul 08, 2026, 11:28 AM UTC
L
Okyo Pharma receives feedback from FDA Type D meeting on urcosimod pathway
Okyo Pharma announced feedback from its FDA Type D meeting, validating the company's regulatory and clinical path forward for urcosimod and supporting advancement into a global Phase 3 pivotal trial for NCP. The FDA feed
EQUITY | Jul 08, 2026, 11:28 AM UTC